# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0213 |
| Population Package | PP-0213 |
| Title | Immunotherapy in Gastric Cancer |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Decision Status | APPROVED / LOCKED |
| QA Basis | CORE_WORKING_RULES v1.7 + FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1 + approved Gold references |

---

# QA Scope

This QA review verifies:

1. locked Decision Batch fidelity;
2. Gold structural compliance;
3. absolute Gold-depth compliance;
4. clinical evidence grounding;
5. current disease-specific guideline alignment;
6. evidence traceability;
7. adjacent-package ownership;
8. patient-facing safety;
9. Knowledge Graph completeness;
10. cross-artifact consistency;
11. repository/package readiness.

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Single educational question | PASS | PP-0213 answers the umbrella clinical question of what immunotherapy is, how it works conceptually, when it is used, and what benefits/limitations/safety issues patients should understand. |
| Scope respected | PASS | The package remains an immunotherapy umbrella and does not become a checkpoint-drug, biomarker-testing, toxicity-management, or response-assessment package. |
| Locked decisions preserved | PASS | The artifact content follows the approved PP-0213 Decision Batch without reopening or changing scope decisions. |
| Core scope complete | PASS | Definition, mechanism, clinical contexts, biomarkers, evidence, benefits, limitations, response patterns, safety, and patient-facing interpretation are covered. |
| Supporting scope complete | PASS | PD-L1, MSI-H/dMMR, TMB-H, HER2 combination, perioperative immunotherapy, landmark trials, and patient misconceptions are represented at approved supporting depth. |
| Explicit exclusions preserved | PASS | Detailed drug management, testing methodology, toxicity algorithms, response methodology, individualized treatment, and detailed neighboring therapies remain excluded. |
| Knowledge blocks complete | PASS | The CKO uses independent knowledge blocks rather than a compressed narrative. |
| Patient explanation complete | PASS | The CKO contains dedicated patient-facing explanations and questions. |
| Common misconceptions addressed | PASS | Major misconceptions regarding PD-L1, universal treatment, toxicity, durable response, progression, and biomarker interpretation are addressed. |
| Clinical safety boundary present | PASS | Safety literacy is included while individualized management is explicitly excluded. |
| Knowledge Graph complete | PASS | Prerequisite, related, and downstream PPs are explicitly identified. |
| Boundary complete | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP ownership is explicitly defined. |
| Adjacent overlap controlled | PASS | Ownership boundaries are established with PP-0209–PP-0212 and PP-0214–PP-0216, plus response/toxicity packages. |

---

# Layer 2 — Clinical QA

| Criterion | Result | QA Note |
|---|---|---|
| Clinical accuracy within approved scope | PASS | Claims are anchored to supplied NCCN, NCI, ACS, and ESMO-ASCO materials. |
| Current NCCN alignment | PASS | Current v2.2026 treatment positioning is used as the primary disease-specific authority. |
| Perioperative immunotherapy correctly represented | PASS | FLOT + durvalumab and selected MSI-H/dMMR perioperative strategies are represented with context and limitations. |
| MATTERHORN nuance preserved | PASS | The diffuse-type limitation and subgroup context are retained; universal benefit is not claimed. |
| Advanced disease pathways correctly framed | PASS | HER2-positive and HER2-negative immunotherapy combinations are described as selected guideline pathways, not individualized prescriptions. |
| PD-L1 interpretation safe | PASS | PD-L1 is described as important but not a universal gatekeeper. |
| MSI-H/dMMR interpretation safe | PASS | MSI-H/dMMR is described as an important immunotherapy context and not as a guaranteed response. |
| TMB-H appropriately qualified | PASS | The limited gastric/GEJ evidence context is explicitly preserved. |
| CheckMate-649 evidence accurately represented | PASS | Population, comparison, and major reported effect measures are included with population context. |
| KEYNOTE-859 evidence accurately represented | PASS | CPS-defined outcomes are presented as trial-population evidence. |
| RATIONALE-305 evidence accurately represented | PASS | All-randomized and TAP-defined outcomes are presented with context. |
| KEYNOTE-811 correctly framed | PASS | HER2-positive combination context is presented without absorbing detailed HER2 ownership. |
| MSI-H subgroup evidence correctly qualified | PASS | Strong subgroup effects are not converted into individual guarantees. |
| Immune toxicity correctly represented | PASS | Multi-organ immune-mediated toxicity is recognized and detailed management is delegated. |
| Response-pattern concepts safe | PASS | Pseudoprogression is not presented as a default explanation for worsening scans. |
| Resistance appropriately qualified | PASS | Primary/acquired resistance is presented conceptually; detailed mechanisms are delegated. |
| No unsupported certainty | PASS | Claims use population-level and context-dependent framing. |
| No individualized medical advice | PASS | No patient-specific prescription or treatment-change instruction is provided. |
| No guideline conflict identified | PASS | No material conflict identified between the project sources within this package's scope. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Technical terms are explained at first use. |
| Patient-friendly wording | PASS | The package uses direct questions, explanations, myths/facts, and patient questions. |
| Logical progression | PASS | The CKO progresses from definition → mechanism → clinical use → biomarkers → evidence → benefit/limitation → safety → response patterns. |
| Mechanism depth appropriate | PASS | Immune checkpoint concepts are explained without becoming a molecular-immunology monograph. |
| Treatment-context clarity | PASS | Perioperative and advanced/metastatic contexts are explicitly distinguished. |
| Biomarker nuance | PASS | PD-L1 and MSI-H/dMMR are explained without turning the package into a testing manual. |
| Patient safety literacy | PASS | The package clearly identifies immune-related toxicity and the importance of reporting new symptoms. |
| Misconception control | PASS | Common high-risk misconceptions are explicitly addressed. |
| Terminology consistency | PASS | Immunotherapy, immune checkpoint inhibitor, PD-1, PD-L1, MSI-H, dMMR, CPS, TAP, HER2, and TMB-H are used consistently. |
| Patient questions included | PASS | A structured question list is provided. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| Governance source-first rule followed | PASS | PP-specific Source Files were searched before production. |
| User-controlled PP sequence respected | PASS | PP-0213 was produced because it was explicitly requested; no next PP was inferred. |
| Decision Batch approved before production | PASS | User explicitly approved and locked the PP-0213 Decision Batch. |
| Gold specification followed | PASS | Four required artifacts are produced with stable naming and structure. |
| Absolute Gold depth followed | PASS | Artifacts are not compact summaries; they preserve substantial clinical reasoning, evidence traceability, Knowledge Graph detail, patient-facing depth, and QA depth. |
| Discussion reference followed | PASS | PP-0112 discussion reference was used for depth, decision logic, boundary style, and organization. |
| Artifact naming compliant | PASS | Exact four-artifact naming standard is used. |
| Versioning compliant | PASS | Version 1.0.0 used for initial Gold production. |
| Evidence traceability | PASS | Primary source set, evidence hierarchy, evidence matrix, claims summary, gaps, and update triggers are included. |
| Boundary architecture | PASS | One clean ownership-oriented Boundary is maintained in final response; artifacts retain scope/exclusion/delegation content without substituting multiple final-response boundaries. |
| Repository readiness | PASS | Package is self-contained and includes all four required Markdown artifacts. |

---

# Gold Depth Integrity QA

## Reference Standard

The project Gold rule states that approved Gold references establish the **minimum expected depth** and that future packages must not:

- compact;
- shorten;
- summarize;
- collapse sections;
- omit substantive reasoning;
- reduce evidence detail;
- reduce QA depth;
- reduce Knowledge Graph detail;
- reduce patient-facing explanatory depth.

## PP-0213 Assessment

### Discussion-to-artifact continuity

PASS.

The artifact package preserves the approved Decision Batch architecture:

- objective;
- evidence discussion;
- MUST DECIDE NOW decisions;
- CAN DEFER;
- scope;
- exclusions;
- adjacent boundaries;
- Knowledge Graph;
- final recommendation.

### CKO depth

PASS.

The CKO includes:

- metadata;
- educational objectives;
- scope;
- clinical knowledge blocks;
- patient explanation;
- clinical importance;
- landmark evidence;
- biomarker interpretation;
- safety;
- response patterns;
- misconceptions;
- key messages;
- patient questions;
- Knowledge Graph;
- safety boundary;
- Boundary;
- revision history.

### Knowledge Passport depth

PASS.

The KP includes:

- identity;
- knowledge classification;
- patient journey;
- runtime use;
- retrieval terms;
- knowledge units;
- evidence classification;
- authoritative sources;
- clinical scope;
- runtime safety rules;
- Knowledge Graph;
- boundary map;
- governance metadata;
- version control.

### Primary Evidence Package depth

PASS.

The EP includes:

- clinical question;
- scope;
- primary sources;
- supporting sources;
- evidence hierarchy;
- evidence matrix;
- landmark trial evidence;
- current guideline context;
- biomarker evidence;
- safety evidence;
- response evidence;
- resistance evidence;
- evidence gaps;
- consistency review;
- claims summary;
- delegation map;
- future update triggers;
- source traceability;
- Boundary verification.

### QA depth

PASS.

The QA report includes all four required layers:

1. Content QA;
2. Clinical QA;
3. Educational QA;
4. Governance QA;

plus explicit Gold-depth integrity, source integrity, boundary integrity, and package-readiness verification.

---

# Cross-Artifact Consistency QA

| Topic | CKO | KP | EP | QA | Result |
|---|---|---|---|---|---|
| PP identity | PP-0213 | PP-0213 | PP-0213 | PP-0213 | PASS |
| Title | Immunotherapy in Gastric Cancer | Same | Same | Same | PASS |
| Core scope | Consistent | Consistent | Consistent | Verified | PASS |
| PD-L1 role | Conceptual | Conceptual | Evidence-supported | Verified | PASS |
| MSI-H/dMMR role | Conceptual | Classification | Evidence-supported | Verified | PASS |
| Perioperative immunotherapy | Core | Core | Evidence | Verified | PASS |
| Advanced immunotherapy | Core | Core | Evidence | Verified | PASS |
| Landmark trials | Present | Indexed | Detailed | Verified | PASS |
| Toxicity | Safety literacy | Runtime rule | Evidence | Verified | PASS |
| Response patterns | Present | Runtime concept | Evidence | Verified | PASS |
| Detailed management excluded | Explicit | Explicit | Delegated | Verified | PASS |
| Knowledge Graph | Present | Present | Delegation | Verified | PASS |
| Boundary | Present | Map | Verification | Verified | PASS |
| Version | 1.0.0 | 1.0.0 | 1.0.0 | 1.0.0 | PASS |

---

# Boundary QA

## Core

Immunotherapy as a gastric/EGJ adenocarcinoma treatment modality; immune/checkpoint mechanism at conceptual clinical depth; immune checkpoint inhibition as the dominant established paradigm; treatment-setting dependence; biomarker relevance at conceptual level; perioperative and advanced/metastatic applications; representative combinations; landmark clinical evidence; benefits, limitations, durable response, resistance concept, unconventional response patterns, immune-related safety awareness, and patient-facing interpretation.

## Supporting

PD-L1 CPS/TAP conceptual context; MSI-H/dMMR relevance; TMB-H as a limited contextual biomarker; HER2 + immunotherapy; FLOT + durvalumab; landmark trials; patient questions and misconceptions.

## Explicitly Excluded

Detailed checkpoint-inhibitor pharmacology; dosing/administration; detailed biomarker testing/scoring; individualized biomarker interpretation; detailed toxicity management; detailed response criteria; individualized treatment selection/sequencing; detailed HER2/CLDN18.2/anti-angiogenic treatment; experimental immunotherapy; individualized prognosis.

## Delegated-to PP

PP-0214; PP-0215; PP-0216; PP-0182; PP-0183; PP-0191; PP-0210; PP-0211; PP-0212; PP-0217; PP-0218; PP-0219; PP-0231; PP-0232; and dedicated sequencing/resistance packages.

### Result

**PASS — ownership is clean and non-duplicative.**

---

# Clinical Safety QA

| Safety Check | Result |
|---|---|
| No individualized treatment recommendation | PASS |
| No dosing instruction | PASS |
| No corticosteroid algorithm | PASS |
| No toxicity grading algorithm | PASS |
| New symptoms during immunotherapy flagged for clinical review | PASS |
| Pseudoprogression not treated as automatic explanation | PASS |
| No promise of cure | PASS |
| No universal biomarker rule | PASS |
| MSI-H/dMMR benefit appropriately qualified | PASS |
| TMB-H evidence limitations disclosed | PASS |

---

# Evidence Gap QA

Known gaps are explicitly documented.

No gap was silently filled with unsupported general knowledge.

The main evidence limitations preserved are:

- biomarker-specific heterogeneity;
- limited TMB-H gastric/GEJ-specific evidence;
- subgroup-size limitations;
- evolving perioperative evidence;
- inability to predict individual response;
- absence of a universal treatment rule.

### Result

**PASS**

---

# Update Trigger QA

The package contains explicit triggers for:

- NCCN treatment changes;
- new checkpoint inhibitors;
- new phase III trials;
- perioperative evidence changes;
- biomarker-threshold changes;
- MSI-H/dMMR pathway changes;
- new immunotherapy biomarkers;
- TMB-H evidence changes;
- immune-toxicity guidance changes;
- response-pattern evidence changes;
- adjacent PP boundary changes.

### Result

**PASS**

---

# Package Integrity QA

Required artifacts:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

### Result

**PASS — all four artifacts present.**

---

# Final QA Decision

## **PASS**

### Rationale

PP-0213:

- follows the approved and locked Decision Batch;
- follows the Gold artifact specification;
- preserves absolute Gold depth;
- uses project Source Files as the primary evidence basis;
- uses NCCN v2.2026 as the primary disease-specific guideline;
- preserves current treatment-context nuance;
- provides substantial patient-facing explanation;
- includes clinically relevant evidence and trial interpretation;
- maintains clear ownership boundaries;
- avoids individualized medical advice;
- includes explicit evidence gaps;
- includes a complete Knowledge Graph;
- includes all required QA layers;
- is repository-ready as a four-artifact Gold package.

---

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**

